Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

Stopped early

Conditions studied: Pancreatic Cancer

In brief

This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.

Key facts

Study ID

NCT03165188

Run by

NewLink Genetics Corporation

People needed

29

Starts

2017-09-01

Expected to finish

2020-12-08

Last updated by the study team

2022-04-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Receipt of at least one dose of algenpantucel-L within the past 15 years
• Signed consent

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Stanford University Cancer Center — Palo Alto, California, United States
• UF Health Cancer Center — Gainesville, Florida, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• NorthShore University HealthSystem — Evanston, Illinois, United States
• Indiana University Health Goshen Center for Cancer Care — Goshen, Indiana, United States
• University of Louisville — Louisville, Kentucky, United States
• Washington University — St Louis, Missouri, United States
• Oregon Health and Science University — Portland, Oregon, United States
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• Baylor College of Medicine — Houston, Texas, United States
• UT Health Cancer Center — San Antonio, Texas, United States
• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.